09/27/23 8:00 AMNasdaq : ARQT managementhigh shortArcutis Appoints L. Todd Edwards as Chief Commercial OfficerArcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stageRHEA-AIneutral
09/25/23 9:00 AMNasdaq : ARQT high shortNew Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic DermatitisArcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the launch of an educational campaign designed to elevate understanding,RHEA-AIneutral
09/19/23 7:30 AMNasdaq : ARQT clinical trialhigh shortArcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trials For the primary endpoint, 25.4% of children treated once daily with roflumilast cream 0.05% achieved Investigator Global Assessment (IGA) SuccessRHEA-AIneutral
09/15/23 4:00 PMNasdaq : ARQT high shortArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 39,000 restricted stockRHEA-AIneutral
09/12/23 7:30 AMNasdaq : ARQT high shortArcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and OlderAtopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States In pivotal Phase 3 trials, roflumilast cream demonstrated statistically significant improvements over vehicle on the primary endpoint of Investigator GlobalRHEA-AIneutral
09/07/23 8:15 AMNasdaq : ARQT high shortArcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)Results for adults and children ages 6 years and older from INTEGUMENT-OLE long-term extension trial highlight that 46.1% and 51.0% of patients who rolled over from the roflumilast cream treatment arm in INTEGUMENT-1 or -2 achieved IGA success at Week 28 and Week 56, respectively Roflumilast creamRHEA-AIneutral
09/05/23 4:00 PMNasdaq : ARQT conferenceshigh shortArcutis to Present at Upcoming Investor ConferenceArcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investorRHEA-AIneutral
09/05/23 7:00 AMNasdaq : AGLE, ARQT managementlow floatAeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-JonesAeglea BioTherapeutics, Inc., a biotechnology company advancing a pipeline of antibody...RHEA-AIpositive
08/31/23 8:00 AMNasdaq : ARQT high shortArcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) ReportArcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stageRHEA-AIneutral
08/29/23 8:00 AMNasdaq : ARQT high shortArcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3% The Cream That Can is a direct-to-consumer ad highlighting that clear skin is possible with ZORYVE ZORYVE is a once-daily, steroid-free cream for individuals with plaque psoriasis 12 years and above that can be used for long-term treatment across all affected areas of the body ZORYVE is included onRHEA-AIneutral